

December 18, 2012


2:00pm–3:00pm

NIH
Building 50
Room 1227

NanoLuc™ Luciferase: A Smaller, Brighter, More Versatile Luciferase

Kyle Hooper, PhD,
Promega Corp.

NanoLuc™ Luciferase, a 19kDa, monomeric luciferase gives a brighter signal and enables more sensitive measurement. The NanoLuc™/Nano-Glo™ Assay is ~100-fold brighter than either firefly or Renilla luciferase in vitro and in cells.



This seminar will address:

- Characteristics and uses of NanoLuc™ Luciferase
- Strategies for handling the bright luminescence
- Considerations for choosing Firefly or NanoLuc™ Luciferase
- Applications of NanoLuc™ Luciferase as a fusion partner for:
 - Protein translocation and degradation
 - Receptor/Ligand Interactions (utilizing BRET)
 - Protein/Protein interactions (utilizing BRET)



Application of NanoLuc™ Luciferase in Drug Screening Assays—

Assay development for neurodegenerative disease targets: Modulating parkin expression in mitochondrial quality control

Samuel Hasson, PhD

Pharmacology Research Fellow,
NINDS and NCTT

REGISTER TODAY!

PLEASE CONTACT:

Charlie Sheen, Ph.D.

Sr. Field Applications Specialist

240-246-5201

charlie.sheen@promega.com